Discounted Cash Flow
Maravai Lifesciences Holdings, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $143.1m | $-731.0k | $7.0m | -0.5% | $-0.03 |
| 2020 | $284.1m (98.5%) | $-10.2m (-1289.3%) | $-10.2m (-245.8%) | -3.6% (-600.0%) | $7.43 (24866.7%) |
| 2021 | $799.2m (181.3%) | $287.2m (2928.0%) | $353.7m (3582.9%) | 35.9% (1105.2%) | $1.59 (-78.6%) |
| 2022 | $883.0m (10.5%) | $270.5m (-5.8%) | $518.9m (46.7%) | 30.6% (-14.8%) | $1.67 (5.0%) |
| 2023 | $288.9m (-67.3%) | $-19.3m (-107.2%) | $60.7m (-88.3%) | -6.7% (-121.9%) | $-0.90 (-153.9%) |
| 2024 | $259.2m (-10.3%) | $-114.8m (-493.3%) | $-22.2m (-136.6%) | -44.3% (-561.4%) | $-1.05 (-16.7%) |
| 2025 | $185.7m (-28.3%) | $-100.0m (12.9%) | $-70.7m (-218.7%) | -53.8% (-21.6%) | $-0.90 (14.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.